Skip to content

Feeding Trial in Pediatric Patients

Enteral Formula Tolerance In Pediatric Patients With Developmental Disabilities

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01469117
Enrollment
16
Registered
2011-11-10
Start date
2011-11-30
Completion date
2013-01-31
Last updated
2014-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Developmental Disabilities

Keywords

Developmental disabilities, Enteral Nutrition, Tube feeding, Nutrition support

Brief summary

This is a single center, prospective, non-randomized, uncontrolled, observational study of the use of an enteral nutrition product in pediatric patients with developmental disabilities.

Detailed description

This prospective observational study seeks to assess ability to achieve enteral feeding goals with a new tube feeding product in pediatric patients with developmental disabilities.

Interventions

Complete feeding of study enteral formula, route and regimen prescribed by the physician

Sponsors

Société des Produits Nestlé (SPN)
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Years to 13 Years
Healthy volunteers
No

Inclusion criteria

* Child aged 1-13 years old with development disabilities * Currently tolerating enteral feeding * Requiring nutritional management to meet 50-90th% weight for age on the Kennedy Kreiger Growth Charts * Requires enteral tube feeding for at least 14 days.

Exclusion criteria

* Unable to access gastrointestinal tract for feeding via tube * Other condition which contraindicates tube feeding

Design outcomes

Primary

MeasureTime frame
Time to feeding goal achievementup to 14 days

Secondary

MeasureTime frame
Gastrointestinal measures assessmentup to 21 days
Percentage of nutrition goal metdaily up to 21 days
Serum biochemical markers assessmentbaseline and completion of study
Assessment of frequency and nature of adverse eventsdaily up to 21 days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026